RET (G810C)

RET · Variant type: point · HGVS: p.G810C

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Pralsetinib	96.0%	4.0%	93.43
2	Tivozanib	94.2%	5.8%	92.42
3	Selpercatinib	89.8%	10.2%	96.72
4	Apatinib	72.1%	27.9%	97.73
5	Ripretinib	66.6%	33.4%	92.95
6	Acalabrutinib	59.4%	40.6%	99.50
7	Repotrectinib	55.3%	44.7%	84.21
8	Sorafenib	54.9%	45.1%	96.72
9	Tenalisib	48.2%	51.8%	97.98
10	Alpelisib	45.4%	54.6%	97.22
11	Entrectinib	42.4%	57.6%	93.69
12	Canertinib	36.3%	63.8%	96.49
13	Fedratinib	32.5%	67.5%	96.21
14	Gilteritinib	25.3%	74.7%	88.97
15	Futibatinib	20.8%	79.2%	98.48
16	Sunitinib	20.4%	79.6%	91.73
17	Erdafitinib	19.4%	80.6%	95.71
18	Upadacitinib	19.0%	81.0%	97.98
19	Paxalisib	17.8%	82.2%	99.75
20	Capivasertib	14.6%	85.4%	96.48
21	Vandetanib	14.4%	85.6%	95.74
22	Quizartinib	13.2%	86.8%	99.50
23	Avapritinib	9.0%	91.0%	97.73
24	Palbociclib	8.7%	91.3%	98.75
25	Defactinib	8.0%	92.0%	92.68

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Pralsetinib	96.0%	100.0%	-4.0%
Tivozanib	94.2%	99.7%	-5.6%
Selpercatinib	89.8%	100.0%	-10.2%
Apatinib	72.1%	—	—
Ripretinib	66.6%	—	—
Acalabrutinib	59.4%	—	—
Repotrectinib	55.3%	—	—
Sorafenib	54.9%	94.0%	-39.0%
Tenalisib	48.2%	98.5%	-50.3%
Alpelisib	45.4%	99.6%	-54.3%
Entrectinib	42.4%	99.6%	-57.2%
Canertinib	36.3%	—	—
Fedratinib	32.5%	99.9%	-67.3%
Gilteritinib	25.3%	100.0%	-74.7%
Futibatinib	20.8%	97.7%	-76.9%
Sunitinib	20.4%	97.2%	-76.9%
Erdafitinib	19.4%	94.7%	-75.3%
Upadacitinib	19.0%	—	—
Paxalisib	17.8%	—	—
Capivasertib	14.6%	—	—
Vandetanib	14.4%	98.6%	-84.2%
Quizartinib	13.2%	—	—
Avapritinib	9.0%	—	—
Palbociclib	8.7%	—	—
Defactinib	8.0%	—	—

Cancer	Organ	Source
carcinoma_lung	Lung	ref
carcinoma_thyroid	Thyroid	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.2ms